Auricular Point Stimulation Plus Dexamethasone for Chemotherapy Nausea
ClinicalTrials.gov Studies
Summary
NIH registered a Phase 2 clinical trial (NCT07537660) on ClinicalTrials.gov evaluating auricular point stimulation combined with dexamethasone for preventing chemotherapy-induced nausea and vomiting in pancreatic cancer patients receiving gemcitabine plus paclitaxel protein-bound treatment. The trial aims to enroll participants who will receive auricular acupressure with bean seeds plus IV dexamethasone as an antiemetic, with a primary completion date of April 17, 2026.
What changed
NIH added a new Phase 2 clinical trial registration to ClinicalTrials.gov. The trial will study whether auricular point stimulation combined with dexamethasone can effectively prevent or suppress nausea and vomiting in pancreatic cancer patients undergoing gemcitabine plus paclitaxel protein-bound chemotherapy.
Healthcare providers and clinical investigators conducting oncology or supportive care research should note this trial's registration. Patients with pancreatic cancer undergoing this specific chemotherapy regimen may be eligible for enrollment. The trial will assess safety, gastrointestinal function, and antiemetic efficacy through daily participant-recorded symptom tracking over a 5-day period following chemotherapy.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Gemcitabine Plus Paclitaxel
Phase 2 NCT07537660 Kind: PHASE2 Apr 17, 2026
Abstract
The goal of this clinical trial is to learn if auricular point stimulation plus dexamethasone works to effectively prevent or suppress nausea and vomiting caused by gemcitabine combined with paclitaxel protein-bound in pancreatic cancer treatment.
It will also learn about the safety and influence on gastrointestinal function of auricular point stimulation plus dexamethasone. The main questions it aims to answer are:
Can auricular point stimulation plus dexamethasone effectively prevent or suppress nausea and vomiting induced by the gemcitabine plus paclitaxel protein-bound regimen? Can auricular point stimulation plus dexamethasone effectively reduce the incidence of appetite loss, weakened or disordered gastrointestinal function, and other uncomfortable conditions caused by excessive use of antiemetic drugs?
Participants will: Receive auricular acupressure with bean seeds on specific points of one ear, plus intravenous injection of dexamethasone as a preventive antiemetic treatment within half an hour before chemotherapy. Starting from the day of chemotherapy (Day 1) to the following five days (Day 1-Day 5), provide regular stimulation at the acupressure points daily by themselves according to the protocol provided in this trial. Record their nausea and vomiting status, appetite, and gastrointestinal function-related symptomatic indicators from Day 1 to Day 5. Oral antiemetics are also prepared. If nausea and vomiting are significant or the patient feels the need, they...
Conditions: Nausea and Vomiting Caused by Chemotherapy
Interventions: Auricular point stimulation plus dexamethasone
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.